Home › Funds › EMERALD ADVISERS, LLC › TVTX

EMERALD ADVISERS, LLC position in TVTX

TRAVERE THERAPEUTICS INC · Health Care

EMERALD ADVISERS, LLC reported holding 1,563,532 shares of TVTX (TRAVERE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$92.1M, representing 2.53% of its reported portfolio and ranking #1 among its reported holdings. EMERALD ADVISERS, LLC has disclosed TVTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)1.56M sh
Reported value held$92.06M
Portfolio Weight2.53%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How EMERALD ADVISERS, LLC's TVTX position evolved

EMERALD ADVISERS, LLC first disclosed a stake in TVTX in Q3 2023 at 1,060,302 shares (US$9.5M). The position peaked in Q3 2026 at 1,563,532 shares, worth US$92.1M. Across 13 filings, EMERALD ADVISERS, LLC increased the stake 6 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,563,532 shares valued at US$92.1M — a reduction of -37,354 shares quarter over quarter.. Notable position changes include a 67% increase in Q1 2024 (shares rose 7% over the following quarter), a 26% trim in Q4 2025 (shares fell 22% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.06M $9.48M New
Q4 2023 1.05M $9.40M Reduce
Q1 2024 1.75M $13.49M Add
Q2 2024 1.64M $13.46M Reduce
Q3 2024 1.96M $27.43M Add
Q4 2024 2.13M $37.03M Add
Q1 2025 2.08M $37.22M Reduce
Q2 2025 2.09M $30.95M Add
Q3 2025 2.15M $51.31M Add
Q4 2025 1.59M $60.91M Reduce
Q1 2026 1.56M $46.26M Reduce
Q2 2026 1.60M $90.95M Add
Q3 2026 1.56M $92.06M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TVTX and 13F data

TVTX (TRAVERE THERAPEUTICS INC) is a Health Care company. 55 other funds we track also report a position in TVTX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$213.2M), Rock Springs Capital Management LP (US$123.8M), Kynam Capital Management, LP (US$113.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TVTX

All TVTX fund holders →

FAQ

How long has EMERALD ADVISERS, LLC held TVTX?

EMERALD ADVISERS, LLC has disclosed TVTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is EMERALD ADVISERS, LLC's current position in TVTX?

As of Q3 2026, EMERALD ADVISERS, LLC holds 1.56M shares of TVTX (TRAVERE THERAPEUTICS INC), valued at $92.06M, representing 2.53% of its reported portfolio and ranking #1.

Has EMERALD ADVISERS, LLC been buying or selling TVTX?

In the latest 13F filing (Q3 2026), EMERALD ADVISERS, LLC reduced its position in TVTX. The position peaked in Q3 2026 at 1.56M shares.

Which other funds hold TVTX?

Other major institutional holders of TVTX include PERCEPTIVE ADVISORS LLC, Rock Springs Capital Management LP, Kynam Capital Management, LP, among 55 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.